National Institute on Drug Abuse; Notice of Closed Meeting, 12540-12541 [2025-04429]

Download as PDF 12540 Federal Register / Vol. 90, No. 51 / Tuesday, March 18, 2025 / Notices property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Eunice Kennedy Shriver National Institute of Child Health and Human Development Special Emphasis Panel; BPCA Pediatric Trials Network Contract Review Meeting. Date: May 5, 2025. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Meeting Format: Virtual Meeting. Address: Eunice Kennedy Shriver National Institute of Child, Health and Human Development, 6710 B Rockledge Drive, Bethesda, MD 20892. Contact Person: Anita Szajek, Ph.D., Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Drive, Room 2131D, Bethesda, MD 20892, (301) 496–5966, email: anita.szajek@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: March 13, 2025. Bruce A. George, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–04431 Filed 3–17–25; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSK9W7S144PROD with NOTICES National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Heart, Lung, and Blood Initial Review Group; Heart, Lung, and Blood Program Project Study Section. Date: April 28–29, 2025. VerDate Sep<11>2014 16:20 Mar 17, 2025 Jkt 265001 Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Meeting Format: Virtual Meeting. Address: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892. Contact Person: Melissa H. Nagelin, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208–R, Bethesda, MD 20892, (301) 827–7951, email: nagelinmh2@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: March 13, 2025. Bruce A. George, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–04430 Filed 3–17–25; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Resource Related Research Projects (R24 Clinical Trial Not Allowed). Date: April 4, 2025. Time: 10:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD 20892. Meeting Format: Video Assisted Meeting. Contact Person: Maryam Rohani, Ph.D., Scientific Review Officer, National Institute of Allergy and Infectious Diseases, National PO 00000 Frm 00018 Fmt 4703 Sfmt 4703 Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD 20892, (301) 761–6656, maryam.rohani@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: March 12, 2025. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–04301 Filed 3–17–25; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, NIDA. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute on Drug Abuse, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIDA. Date: May 06, 2025. Time: 10:00 a.m. to 4:45 p.m. Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Meeting Format: Virtual Meeting. Place: National Institute on Drug Abuse, NIH, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224. Contact Person: Megan E. Bollinger, M.S., Management Analyst, Office of the Scientific Director, National Institute on Drug Abuse, 251 Bayview Boulevard, Suite 200, Baltimore, MD 21224, (667) 312–5035 email: Megan.Bollinger@nih.gov Contact Person: Deon Harvey, Ph.D., Management Analyst, Office of the Scientific Director, National Institute on Drug Abuse, 251 Bayview Boulevard, Suite 200, Baltimore, MD 21224, (667) 312–5568, email: Deon.Harvey@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction E:\FR\FM\18MRN1.SGM 18MRN1 Federal Register / Vol. 90, No. 51 / Tuesday, March 18, 2025 / Notices Research Programs, National Institutes of Health, HHS) Dated: March 13, 2025. Bruce A. George, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–04429 Filed 3–17–25; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings khammond on DSK9W7S144PROD with NOTICES Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Developmental Biology. Date: April 23, 2025. Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Meeting Format: Virtual Meeting. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Ezgi Kunttas-Tatli, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–7047, email: ezgi.kunttastatli@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Physiology and Pathobiology of Cardiovascular and Respiratory Systems. Date: May 1–2, 2025. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications Meeting Format: Virtual Meeting. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Yuanyi Feng, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of VerDate Sep<11>2014 16:20 Mar 17, 2025 Jkt 265001 Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 594–1180, email: fengy7@ csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Special Topics in Neural Disorders and Clinical Neuroscience. Date: May 5, 2025. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Meeting Format: Virtual Meeting. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Paula Elyse Schauwecker, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5201, Bethesda, MD 20892, 301–760–8207, email: schauweckerpe@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Collaborative Applications: Clinical Studies of Mental Illness. Date: May 5, 2025. Time: 5:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Meeting Format: Virtual Meeting. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Paula Elyse Schauwecker, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5201, Bethesda, MD 20892, 301–760–8207, email: schauweckerpe@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Alcohol and Motivated Behavior. Date: May 7, 2025. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Meeting Format: Virtual Meeting. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Kathryn Partlow, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1016D, Bethesda, MD 20892, (301) 594–2138, email: partlowkc@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: March 13, 2025. Bruce A. George, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–04421 Filed 3–17–25; 8:45 am] PO 00000 Frm 00019 Fmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select AntibioticResistant Gram-Negative Bacteria (R01 Clinical Trial Not Allowed). Date: April 24, 2025. Time: 9:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F21B, Rockville, MD 20892 (Video Assisted Meeting). Contact Person: Maryam Feili-Hariri, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F21B, Rockville, MD 20892, 240–669–5026, haririmf@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: March 13, 2025. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2025–04435 Filed 3–17–25; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P Sfmt 4703 12541 E:\FR\FM\18MRN1.SGM 18MRN1

Agencies

[Federal Register Volume 90, Number 51 (Tuesday, March 18, 2025)]
[Notices]
[Pages 12540-12541]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-04429]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Board of Scientific 
Counselors, NIDA. The meeting will be closed to the public as indicated 
below in accordance with the provisions set forth in section 
552b(c)(6), title 5 U.S.C., as amended for the review, discussion, and 
evaluation of individual intramural programs and projects conducted by 
the National Institute on Drug Abuse, including consideration of 
personnel qualifications and performance, and the competence of 
individual investigators, the disclosure of which would constitute a 
clearly unwarranted invasion of personal privacy.

    Name of Committee: Board of Scientific Counselors, NIDA.
    Date: May 06, 2025.
    Time: 10:00 a.m. to 4:45 p.m.
    Agenda: To review and evaluate personnel qualifications and 
performance, and competence of individual investigators.
    Meeting Format: Virtual Meeting.
    Place: National Institute on Drug Abuse, NIH, Biomedical 
Research Center, 251 Bayview Boulevard, Baltimore, MD 21224.
    Contact Person: Megan E. Bollinger, M.S., Management Analyst, 
Office of the Scientific Director, National Institute on Drug Abuse, 
251 Bayview Boulevard, Suite 200, Baltimore, MD 21224, (667) 312-
5035 email: [email protected]
    Contact Person: Deon Harvey, Ph.D., Management Analyst, Office 
of the Scientific Director, National Institute on Drug Abuse, 251 
Bayview Boulevard, Suite 200, Baltimore, MD 21224, (667) 312-5568, 
email: [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction

[[Page 12541]]

Research Programs, National Institutes of Health, HHS)

    Dated: March 13, 2025.
Bruce A. George,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2025-04429 Filed 3-17-25; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.